These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24060868)

  • 21. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
    Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
    Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.
    Serre SB; Jensen SB; Ghanem L; Humes DG; Ramirez S; Li YP; Krarup H; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3563-78. PubMed ID: 27021330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.
    Mathiesen CK; Prentoe J; Meredith LW; Jensen TB; Krarup H; McKeating JA; Gottwein JM; Bukh J
    J Virol; 2015 Aug; 89(15):7758-75. PubMed ID: 25995244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).
    Imhof I; Simmonds P
    Hepatology; 2011 Apr; 53(4):1090-9. PubMed ID: 21480315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance.
    Jensen SB; Serre SB; Humes DG; Ramirez S; Li YP; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7426-36. PubMed ID: 26392503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy.
    Chusri P; Kumthip K; Pantip C; Thongsawat S; O'Brien A; Maneekarn N
    Virus Res; 2015 Jan; 196():37-43. PubMed ID: 25445343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77.
    Li YP; Ramirez S; Mikkelsen L; Bukh J
    J Virol; 2015 Jan; 89(1):811-23. PubMed ID: 25355880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
    Scheel TK; Gottwein JM; Mikkelsen LS; Jensen TB; Bukh J
    Gastroenterology; 2011 Mar; 140(3):1032-42. PubMed ID: 21111742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
    Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
    Lenz O; Verbinnen T; Lin TI; Vijgen L; Cummings MD; Lindberg J; Berke JM; Dehertogh P; Fransen E; Scholliers A; Vermeiren K; Ivens T; Raboisson P; Edlund M; Storm S; Vrang L; de Kock H; Fanning GC; Simmen KA
    Antimicrob Agents Chemother; 2010 May; 54(5):1878-87. PubMed ID: 20176898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
    Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system.
    Cheng G; Chan K; Yang H; Corsa A; Pokrovskii M; Paulson M; Bahador G; Zhong W; Delaney W
    Antimicrob Agents Chemother; 2011 May; 55(5):2197-205. PubMed ID: 21357305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
    Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
    Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amino Acid Mutations in the NS4A Region of Hepatitis C Virus Contribute to Viral Replication and Infectious Virus Production.
    Murayama A; Sugiyama N; Suzuki R; Moriyama M; Nakamura N; Mochizuki H; Wakita T; Kato T
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.
    Wyles DL; Kaihara KA; Schooley RT
    Antimicrob Agents Chemother; 2008 May; 52(5):1862-4. PubMed ID: 18332167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.
    Verbinnen T; Fevery B; Vijgen L; Jacobs T; De Meyer S; Lenz O
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7548-57. PubMed ID: 26392483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease.
    Welsch C; Shimakami T; Hartmann C; Yang Y; Domingues FS; Lengauer T; Zeuzem S; Lemon SM
    Gastroenterology; 2012 Mar; 142(3):654-63. PubMed ID: 22155364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.
    Pham LV; Pedersen MS; Fahnøe U; Fernandez-Antunez C; Humes D; Schønning K; Ramirez S; Bukh J
    Gut; 2022 Mar; 71(3):627-642. PubMed ID: 33833066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.